logo-loader
HealthCannabis
Xphyto Therapeutics Corp.

Full interview: Xphyto Therapeutics acquires Vektor Pharma as company looks for rapid growth

Xphyto Therapeutics (CSE: XPHY) CEO Hugh Rogers sat down with Steve Darling from Proactive Vancouver with details about a key acquisition the company has made buying Vektor Pharma. They are a small German narcotics company. 

Rogers telling Proactive why this deal will accelerate the company’s plans for medical cannabis in Germany. Rogers also shared details about the thin film delivery system they have also acquired. 

Quick facts: Xphyto Therapeutics Corp.

Price: $1.29

Market: CSE
Market Cap: $60.77 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Xphyto Therapeutics Corp. named herein, including the promotion by the Company of Xphyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

More on this story

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

7 hours, 26 minutes ago

2 min read